Nov 06, 2019
Ardelyx Announces Presentation at Kidney Week 2019
Nov 06, 2019
Ardelyx Reports Third Quarter 2019 Financial Results and Recent Highlights
Oct 10, 2019
Ardelyx to Host Analyst Day in New York
Sep 17, 2019
Ardelyx to Present at the Ladenburg Thalmann 2019 Healthcare Conference
Sep 03, 2019
Ardelyx Announces Positive Results from the Pivotal Phase 3 AMPLIFY Study Evaluating Tenapanor in Dialysis Patients Who Have Uncontrolled Hyperphosphatemia Despite Phosphate Binder Treatment
Sep 02, 2019
Ardelyx to Host Conference Call on September 3 to Review Results from the Pivotal Phase 3 AMPLIFY Study
Jun 25, 2019
US Nephrologists Report Few Gains in the CKD-MBD Market for Akebia's Auryxia, Amgen's Parsabiv, and Opko's Rayaldee Despite Reports That They Would Like to Expand Use of All Three Products
May 07, 2019
Ardelyx Reports First Quarter 2019 Financial Results and Recent Business Highlights
Mar 07, 2019
Ardelyx Announces Peer-Reviewed Publication of Positive Phase 3 Results of Tenapanor for the Treatment of Hyperphosphatemia in the Journal of the American Society of Nephrology
Feb 07, 2019
Ardelyx Collaboration Partner, Kyowa Hakko Kirin, Announces Initiation of a Phase 2 Clinical Study of Tenapanor for Hyperphosphatemia Patients on Dialysis in Japan
Nov 07, 2018
Ardelyx Reports Third Quarter 2018 Financial Results and Recent Highlights
Oct 26, 2018
Ardelyx Presents New Preclinical Data Demonstrating Synergy between Tenapanor and Sevelamer When Dosed in Combination for Elevated Serum Phosphorus
Oct 04, 2018
Ardelyx to Host Its First Annual Investor Day Focused on Treatment Landscape of Renal Disorders
Aug 29, 2018
Ardelyx Announces Science Translational Medicine Publication Detailing Tenapanor's Unique Mechanism of Action Inhibiting Paracellular Phosphate Absorption
Nov 28, 2017
Ardelyx and Kyowa Hakko Kirin Announce License Agreement for Tenapanor for Cardiorenal Diseases in Japan
Nov 14, 2017
In the CKD-MBD Market, OPKO's Rayaldee Continues to Struggle While Keryx's Auryxia Gains Momentum, According to Latest Quarterly Update from Spherix Global Insights